Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

Debra L. Richardson, Floor J. Backes, Leigh G. Seamon, Vanna Zanagnolo, David M. O'Malley, David E. Cohn, Jeffrey M. Fowler, Larry J. Copeland

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Objective: To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC). Methods: A chart review of all patients with recurrent EOC who were treated with D1, D15 GPB in a 28-day cycle at a single institution was performed. Standard doses were gemcitabine 1000 mg/m2, cisplatin 30 mg/m2 or carboplatin AUC 3, and bevacizumab 10 mg/kg. All patients were analyzed for toxicity. RR and PFS were assessed in all patients who received at least 2 cycles of GPB. Results: Thirty-five patients were identified, and 33 received at least 2 cycles of GPB. The majority of patients (80%) were platinum sensitive. Patients received a median of 6 cycles of GPB (range 1-24). Sixteen patients (48%) had a complete response (CR), and 10 patients (30%) had a partial response (PR), for a total RR of 78%. An additional 5 patients (15%) had stable disease, and only 2 (6%) patients had progressive disease. The median overall PFS was 12 months (95% CI 7-15), with a median follow-up time of 10 months (2-22). Two patients (6%) had bowel perforations, and both survived. Hematologic toxicities were most common, with 29% and 14% of patients experiencing grade 3 or 4 neutropenia and thrombocytopenia respectively. Conclusions: The combination of GPB demonstrated excellent efficacy for the treatment of recurrent EOC. However, serious toxicities occurred, and the safety profile of this combination requires further study.

Original languageEnglish (US)
Pages (from-to)461-466
Number of pages6
JournalGynecologic Oncology
Volume111
Issue number3
DOIs
StatePublished - Dec 2008

Fingerprint

gemcitabine
Platinum
Ovarian Neoplasms
Therapeutics
Disease-Free Survival
Bevacizumab

Keywords

  • Bevacizumab
  • Bowel perforation
  • Gemcitabine
  • Platinum
  • Recurrent epithelial ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Richardson, D. L., Backes, F. J., Seamon, L. G., Zanagnolo, V., O'Malley, D. M., Cohn, D. E., ... Copeland, L. J. (2008). Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecologic Oncology, 111(3), 461-466. https://doi.org/10.1016/j.ygyno.2008.08.011

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. / Richardson, Debra L.; Backes, Floor J.; Seamon, Leigh G.; Zanagnolo, Vanna; O'Malley, David M.; Cohn, David E.; Fowler, Jeffrey M.; Copeland, Larry J.

In: Gynecologic Oncology, Vol. 111, No. 3, 12.2008, p. 461-466.

Research output: Contribution to journalArticle

Richardson, DL, Backes, FJ, Seamon, LG, Zanagnolo, V, O'Malley, DM, Cohn, DE, Fowler, JM & Copeland, LJ 2008, 'Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer', Gynecologic Oncology, vol. 111, no. 3, pp. 461-466. https://doi.org/10.1016/j.ygyno.2008.08.011
Richardson, Debra L. ; Backes, Floor J. ; Seamon, Leigh G. ; Zanagnolo, Vanna ; O'Malley, David M. ; Cohn, David E. ; Fowler, Jeffrey M. ; Copeland, Larry J. / Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. In: Gynecologic Oncology. 2008 ; Vol. 111, No. 3. pp. 461-466.
@article{f15ee11e92204c828d0941d245c9b392,
title = "Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer",
abstract = "Objective: To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC). Methods: A chart review of all patients with recurrent EOC who were treated with D1, D15 GPB in a 28-day cycle at a single institution was performed. Standard doses were gemcitabine 1000 mg/m2, cisplatin 30 mg/m2 or carboplatin AUC 3, and bevacizumab 10 mg/kg. All patients were analyzed for toxicity. RR and PFS were assessed in all patients who received at least 2 cycles of GPB. Results: Thirty-five patients were identified, and 33 received at least 2 cycles of GPB. The majority of patients (80{\%}) were platinum sensitive. Patients received a median of 6 cycles of GPB (range 1-24). Sixteen patients (48{\%}) had a complete response (CR), and 10 patients (30{\%}) had a partial response (PR), for a total RR of 78{\%}. An additional 5 patients (15{\%}) had stable disease, and only 2 (6{\%}) patients had progressive disease. The median overall PFS was 12 months (95{\%} CI 7-15), with a median follow-up time of 10 months (2-22). Two patients (6{\%}) had bowel perforations, and both survived. Hematologic toxicities were most common, with 29{\%} and 14{\%} of patients experiencing grade 3 or 4 neutropenia and thrombocytopenia respectively. Conclusions: The combination of GPB demonstrated excellent efficacy for the treatment of recurrent EOC. However, serious toxicities occurred, and the safety profile of this combination requires further study.",
keywords = "Bevacizumab, Bowel perforation, Gemcitabine, Platinum, Recurrent epithelial ovarian cancer",
author = "Richardson, {Debra L.} and Backes, {Floor J.} and Seamon, {Leigh G.} and Vanna Zanagnolo and O'Malley, {David M.} and Cohn, {David E.} and Fowler, {Jeffrey M.} and Copeland, {Larry J.}",
year = "2008",
month = "12",
doi = "10.1016/j.ygyno.2008.08.011",
language = "English (US)",
volume = "111",
pages = "461--466",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

AU - Richardson, Debra L.

AU - Backes, Floor J.

AU - Seamon, Leigh G.

AU - Zanagnolo, Vanna

AU - O'Malley, David M.

AU - Cohn, David E.

AU - Fowler, Jeffrey M.

AU - Copeland, Larry J.

PY - 2008/12

Y1 - 2008/12

N2 - Objective: To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC). Methods: A chart review of all patients with recurrent EOC who were treated with D1, D15 GPB in a 28-day cycle at a single institution was performed. Standard doses were gemcitabine 1000 mg/m2, cisplatin 30 mg/m2 or carboplatin AUC 3, and bevacizumab 10 mg/kg. All patients were analyzed for toxicity. RR and PFS were assessed in all patients who received at least 2 cycles of GPB. Results: Thirty-five patients were identified, and 33 received at least 2 cycles of GPB. The majority of patients (80%) were platinum sensitive. Patients received a median of 6 cycles of GPB (range 1-24). Sixteen patients (48%) had a complete response (CR), and 10 patients (30%) had a partial response (PR), for a total RR of 78%. An additional 5 patients (15%) had stable disease, and only 2 (6%) patients had progressive disease. The median overall PFS was 12 months (95% CI 7-15), with a median follow-up time of 10 months (2-22). Two patients (6%) had bowel perforations, and both survived. Hematologic toxicities were most common, with 29% and 14% of patients experiencing grade 3 or 4 neutropenia and thrombocytopenia respectively. Conclusions: The combination of GPB demonstrated excellent efficacy for the treatment of recurrent EOC. However, serious toxicities occurred, and the safety profile of this combination requires further study.

AB - Objective: To describe the response rate (RR), progression-free survival (PFS), and toxicity profile of combination gemcitabine, platinum, and bevacizumab (GPB) for the treatment of recurrent epithelial ovarian cancer (EOC). Methods: A chart review of all patients with recurrent EOC who were treated with D1, D15 GPB in a 28-day cycle at a single institution was performed. Standard doses were gemcitabine 1000 mg/m2, cisplatin 30 mg/m2 or carboplatin AUC 3, and bevacizumab 10 mg/kg. All patients were analyzed for toxicity. RR and PFS were assessed in all patients who received at least 2 cycles of GPB. Results: Thirty-five patients were identified, and 33 received at least 2 cycles of GPB. The majority of patients (80%) were platinum sensitive. Patients received a median of 6 cycles of GPB (range 1-24). Sixteen patients (48%) had a complete response (CR), and 10 patients (30%) had a partial response (PR), for a total RR of 78%. An additional 5 patients (15%) had stable disease, and only 2 (6%) patients had progressive disease. The median overall PFS was 12 months (95% CI 7-15), with a median follow-up time of 10 months (2-22). Two patients (6%) had bowel perforations, and both survived. Hematologic toxicities were most common, with 29% and 14% of patients experiencing grade 3 or 4 neutropenia and thrombocytopenia respectively. Conclusions: The combination of GPB demonstrated excellent efficacy for the treatment of recurrent EOC. However, serious toxicities occurred, and the safety profile of this combination requires further study.

KW - Bevacizumab

KW - Bowel perforation

KW - Gemcitabine

KW - Platinum

KW - Recurrent epithelial ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=56449105264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449105264&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.08.011

DO - 10.1016/j.ygyno.2008.08.011

M3 - Article

C2 - 18829088

AN - SCOPUS:56449105264

VL - 111

SP - 461

EP - 466

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -